Zilia, led by CEO Patrick Sauvageau, is a medical technology company developing a platform to non-invasively measure biomarkers in the eye. Its flagship product, the Zilia Ocular, focuses initially on ocular oximetry. The technology integrates photonics and artificial intelligence to leverage the eye’s optical properties and its direct connections to the vascular system and the brain. The company intends to use the recent bridge funds to scale commercialization of the Zilia Ocular. Zilia closed an undisclosed bridge financing on May 7, 2025, with backers including Linearis Ventures. The round was described as bridge funding; the total amount was not disclosed. Zilia is advancing Zilia Ocular, a retinal camera designed to measure oxygen saturation in the eye to enable earlier diagnosis and management of ocular diseases. The company says its platform technology can be adapted to assess a wide array of biomarkers in the eye, enabling potential applications in neurology, cardiology, oncology and more. Zilia intends to use the new funding to complete the regulatory approval process for the clinical launch of Zilia Ocular. The company is led by co-founder and CEO Patrick Sauvageau. Zilia is based in Quebec, Canada. The article does not disclose operating metrics such as revenue or user counts.

Total raised

$4M

Funding rounds

2

Latest round

Seed

Latest activity

Aug 2021